Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-70 years of age;~* rheumatoid arthritis for \>= 6 months;~* receiving permitted DMARDs, at a stable dose, for \>= 8 weeks prior to baseline;~* current inadequate clinical response to DMARDs.~Exclusion Criteria:~* major surgery, including joint surgery, within 8 weeks before entering study, or planned major surgery within 6 months following randomization;~* rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;~* unsuccessful treatment with an anti-TNF agent;~* previous treatment with tocilizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).